Free Trial
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel Free AAPG Stock Alerts

Ascentage Pharma Group International (AAPG) Competitors

Ascentage Pharma Group International logo
$14.94 -1.15 (-7.15%)
Closing price 03:53 PM Eastern
Extended Trading
$14.85 -0.09 (-0.60%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

AAPG vs. ORKA, COGT, MIRM, TVTX, and CRSP

Should you buy Ascentage Pharma Group International stock or one of its competitors? Ascentage Pharma Group International's main competitors and comparable companies include Oruka Therapeutics (ORKA), Cogent Biosciences (COGT), Mirum Pharmaceuticals (MIRM), Travere Therapeutics (TVTX), and CRISPR Therapeutics (CRSP). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ascentage Pharma Group International compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and Ascentage Pharma Group International (NASDAQ:AAPG) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Ascentage Pharma Group International's return on equity of 0.00% beat Oruka Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Oruka TherapeuticsN/A -21.65% -20.88%
Ascentage Pharma Group International N/A N/A N/A

Oruka Therapeutics currently has a consensus price target of $128.91, indicating a potential upside of 60.77%. Ascentage Pharma Group International has a consensus price target of $46.43, indicating a potential upside of 188.56%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, analysts plainly believe Ascentage Pharma Group International is more favorable than Oruka Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Oruka Therapeutics
1 Sell rating(s)
0 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.82
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20

Oruka Therapeutics has a beta of -0.37, suggesting that its stock price is 137% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.12, suggesting that its stock price is 88% less volatile than the broader market.

In the previous week, Oruka Therapeutics had 3 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 5 mentions for Oruka Therapeutics and 2 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 1.69 beat Oruka Therapeutics' score of 0.57 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Oruka Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

56.4% of Oruka Therapeutics shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oruka Therapeutics has higher earnings, but lower revenue than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oruka TherapeuticsN/AN/A-$105.43M-$2.03N/A
Ascentage Pharma Group International$82.10M18.30-$177.71MN/AN/A

Summary

Ascentage Pharma Group International beats Oruka Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Ascentage Pharma Group International (NASDAQ:AAPG) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Cogent Biosciences and Cogent Biosciences both had 2 articles in the media. Ascentage Pharma Group International's average media sentiment score of 1.69 beat Cogent Biosciences' score of 0.51 indicating that Ascentage Pharma Group International is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cogent Biosciences
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive

Cogent Biosciences has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Ascentage Pharma Group International has a beta of 0.12, meaning that its share price is 88% less volatile than the broader market.

Cogent Biosciences presently has a consensus price target of $51.56, suggesting a potential upside of 69.70%. Ascentage Pharma Group International has a consensus price target of $46.43, suggesting a potential upside of 188.56%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, analysts clearly believe Ascentage Pharma Group International is more favorable than Cogent Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cogent Biosciences
1 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.75
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20

Ascentage Pharma Group International has higher revenue and earnings than Cogent Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cogent BiosciencesN/AN/A-$328.94M-$2.16N/A
Ascentage Pharma Group International$82.10M18.30-$177.71MN/AN/A

Ascentage Pharma Group International's return on equity of 0.00% beat Cogent Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cogent BiosciencesN/A -84.47% -47.72%
Ascentage Pharma Group International N/A N/A N/A

Summary

Ascentage Pharma Group International beats Cogent Biosciences on 8 of the 9 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Mirum Pharmaceuticals?

Ascentage Pharma Group International (NASDAQ:AAPG) and Mirum Pharmaceuticals (NASDAQ:MIRM) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, institutional ownership, valuation, risk, earnings and media sentiment.

Ascentage Pharma Group International presently has a consensus target price of $46.43, indicating a potential upside of 188.56%. Mirum Pharmaceuticals has a consensus target price of $142.56, indicating a potential upside of 79.89%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ascentage Pharma Group International is more favorable than Mirum Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
Mirum Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93

Mirum Pharmaceuticals has higher revenue and earnings than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M18.30-$177.71MN/AN/A
Mirum Pharmaceuticals$521.31M9.87-$23.36M-$14.55N/A

Ascentage Pharma Group International has a beta of 0.12, suggesting that its share price is 88% less volatile than the broader market. Comparatively, Mirum Pharmaceuticals has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market.

Ascentage Pharma Group International has a net margin of 0.00% compared to Mirum Pharmaceuticals' net margin of -139.18%. Ascentage Pharma Group International's return on equity of 0.00% beat Mirum Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
Mirum Pharmaceuticals -139.18%-36.28%-8.54%

In the previous week, Ascentage Pharma Group International and Ascentage Pharma Group International both had 2 articles in the media. Ascentage Pharma Group International's average media sentiment score of 1.69 beat Mirum Pharmaceuticals' score of 0.85 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Mirum Pharmaceuticals
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Ascentage Pharma Group International beats Mirum Pharmaceuticals on 8 of the 12 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to Travere Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Ascentage Pharma Group International has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market.

Ascentage Pharma Group International presently has a consensus target price of $46.43, indicating a potential upside of 188.56%. Travere Therapeutics has a consensus target price of $69.50, indicating a potential upside of 24.15%. Given Ascentage Pharma Group International's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ascentage Pharma Group International is more favorable than Travere Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
Travere Therapeutics
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.75

Travere Therapeutics has higher revenue and earnings than Ascentage Pharma Group International.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M18.30-$177.71MN/AN/A
Travere Therapeutics$490.73M10.75-$25.55M-$0.46N/A

In the previous week, Ascentage Pharma Group International and Ascentage Pharma Group International both had 2 articles in the media. Ascentage Pharma Group International's average media sentiment score of 1.69 beat Travere Therapeutics' score of 0.00 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Travere Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ascentage Pharma Group International has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Ascentage Pharma Group International's return on equity of 0.00% beat Travere Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
Travere Therapeutics -7.35%-55.15%-6.88%

Summary

Ascentage Pharma Group International beats Travere Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Ascentage Pharma Group International compare to CRISPR Therapeutics?

Ascentage Pharma Group International (NASDAQ:AAPG) and CRISPR Therapeutics (NASDAQ:CRSP) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

Ascentage Pharma Group International has higher revenue and earnings than CRISPR Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ascentage Pharma Group International$82.10M18.30-$177.71MN/AN/A
CRISPR Therapeutics$3.51M1,487.54-$581.60M-$4.76N/A

Ascentage Pharma Group International presently has a consensus target price of $46.43, indicating a potential upside of 188.56%. CRISPR Therapeutics has a consensus target price of $67.94, indicating a potential upside of 25.82%. Given Ascentage Pharma Group International's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ascentage Pharma Group International is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ascentage Pharma Group International
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
3.20
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
9 Buy rating(s)
2 Strong Buy rating(s)
2.67

In the previous week, CRISPR Therapeutics had 7 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 9 mentions for CRISPR Therapeutics and 2 mentions for Ascentage Pharma Group International. Ascentage Pharma Group International's average media sentiment score of 1.69 beat CRISPR Therapeutics' score of 0.27 indicating that Ascentage Pharma Group International is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ascentage Pharma Group International
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
CRISPR Therapeutics
3 Very Positive mention(s)
1 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Ascentage Pharma Group International has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. Ascentage Pharma Group International's return on equity of 0.00% beat CRISPR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Ascentage Pharma Group InternationalN/A N/A N/A
CRISPR Therapeutics -3,368.72%-24.39%-18.25%

69.2% of CRISPR Therapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Ascentage Pharma Group International has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.76, indicating that its stock price is 76% more volatile than the broader market.

Summary

Ascentage Pharma Group International beats CRISPR Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Ascentage Pharma Group International News Delivered to You Automatically

Sign up to receive the latest news and ratings for AAPG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AAPG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AAPG vs. The Competition

Export
MetricAscentage Pharma Group InternationalBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.40B$3.85B$7.19B$13.38B
Dividend YieldN/A3.65%2.53%17.39%
P/E RatioN/A13.60275.1126.15
Price / Sales17.001,231.10634.19106.70
Price / CashN/A126.5679.4153.24
Price / Book7.3215.9810.746.27
Net Income-$177.71M-$22.65M$3.50B$382.03M
7 Day Performance-9.23%-4.52%-1.55%-0.85%
1 Month Performance-15.16%-12.53%-6.73%-5.29%
1 Year Performance-61.57%13.36%5.67%0.73%

Ascentage Pharma Group International Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AAPG
Ascentage Pharma Group International
3.1879 of 5 stars		$14.94
-7.1%		$46.43
+210.8%		-59.6%$1.40B$82.10MN/A767
ORKA
Oruka Therapeutics
2.9511 of 5 stars		$83.59
+0.2%		$128.91
+54.2%		+294.4%$5.53BN/AN/A68
COGT
Cogent Biosciences
2.4778 of 5 stars		$31.02
-1.8%		$51.56
+66.2%		+91.1%$5.37BN/AN/A258
MIRM
Mirum Pharmaceuticals
2.7517 of 5 stars		$82.67
-1.5%		$142.56
+72.4%		+9.3%$5.37B$521.31MN/A433
TVTX
Travere Therapeutics
2.3594 of 5 stars		$56.61
-0.4%		$69.50
+22.8%		+114.2%$5.34B$490.73MN/A497

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:AAPG) was last updated on 10/7/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel